Skip to main content

ASCPT 2024 Annual Meeting Main banner

Early Development & Drug Safety (EDDS)

Early Development & Drug Safety (EDDS)

Type here to filter the list

LB-022 - MULTIPLE ELIMINATION PATHWAYS ARE RESPONSIBLE FOR THE ELIMINATION OF ETRUMADENANT (ETRUMA) AFTER ORAL ADMINISTRATION OF [14C]-ETRUMA TO HUMANS.

Favorite
PT-027 - INHIBITION OF TACROLIMUS METABOLISM BY CANNABIDIOL AND ITS METABOLITES IN VITRO.

Favorite
PII-025 - ASCENDING DOSE IN VIVO QT STUDIES HAVE THE SENSITIVITY TO DETECT QT INTERVAL CHANGES THAT ARE SUFFICIENT TO SUPPORT A CLINICAL QT WAIVER: ASSESSMENT OF QT/QTC INTERVAL CHANGES USING AN ESCALATING DOSE DESIGN IN TELEMETERED BEAGLE DOGS.

Favorite
PII-026 - COMPARISON OF CHANGES IN PUPIL DIAMETER AND HYPERCAPNIC VENTILATION FOR OXYCODONE AND PSYCHOTROPIC DRUGS ADMINISTERED ALONE OR IN COMBINATION

Favorite
PII-027 - FORMULATION IMPACT OF SSZ ON MTX EXPOSURE: A REPEAT DDI STUDY FOR A MK2 INHIBITOR BMS-986371

Favorite
PII-028 - NO PHOTOTOXICITY OR PHOTOALLERGY EFFECT WITH MRX-5LBT (10%) LIDOCAINE PATCH ADMINISTRATION

Favorite
PII-029 - PHARMACOKINETIC EVALUATION OF GB1211 IN A NOVEL TABLET FORMULATION, ADMINISTERED UNDER FASTED AND FED CONDITIONS, AND COMPARED TO GB1211 CAPSULES, IN HEALTHY VOLUNTEERS

Favorite
PII-030 - PHASE 1 EVALUATION OF THE SAFETY, TOLERABILITY AND PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS OF THE ADENOSINE A1R/A3R AGONIST AST-004 AFTER INTRAVENOUS INFUSION IN HEALTHY VOLUNTEERS

Favorite
PII-031 - REVIEW OF TRANSLATIONAL CANCER RESEARCH TARGETING ADENOSINE RECEPTOR A2AR.

Favorite
PII-032 - WHAT TO EXPECT FROM A PHENYTOIN DRUG-DRUG INTERACTION STUDY: ADVERSE EVENT PROFILING AND SAFETY ASSESSMENT

Favorite
TIP-002 - DRUG-GENE-NUTRACEUTICAL INTERACTIONS OF CANNABIDIOL AND TACROLIMUS.

Favorite
TIP-003 - EVALUATING THE IMPACT OF XIAO-CHAI-HU-TANG ON PHARMACOKINETIC BEHAVIORS OF IRINOTECAN, RALOXIFENE AND THEIR METABOLITES IN HUMANS: A RUN-IN SAFETY STUDY.

Favorite